Literature DB >> 2886207

Antagonism of xylazine induced sedation by idazoxan in calves.

T J Doherty, J A Ballinger, W N McDonell, P J Pascoe, A E Valliant.   

Abstract

Idazoxan was studied at three dose rates to assess its potential as an antagonist to xylazine. Calves in the study group were initially given xylazine at a dose rate of 0.2 mg/kg intravenously followed 12 minutes later by idazoxan at a dose rate of either 0.05, 0.075 or 0.10 mg/kg intravenously. A control group received a saline injection instead of idazoxan. All three dose levels of idazoxan successfully reversed the xylazine induced central nervous depression and all animals stood within two minutes of injection. No residual signs of sedation were noticed and relapse did not occur. In addition idazoxan was successful in reversing respiratory and cardiovascular depression produced by xylazine. The results indicated that idazoxan may be used for rapid reversal of xylazine induced sedation in calves.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886207      PMCID: PMC1255312     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  18 in total

1.  Cardiopulmonary effects of xylazine in dogs.

Authors:  A M Klide; H W Calderwood; L R Soma
Journal:  Am J Vet Res       Date:  1975-07       Impact factor: 1.156

2.  Cardiovascular and respiratory effects of xylazine in sheep.

Authors:  M A Aziz; S S Carlyle
Journal:  Zentralbl Veterinarmed A       Date:  1978-04

3.  Central and peripheral effects of 2-(2,6-dimethylphenylamino)-4-H-5,6-dihydro-1,3-thiazin (Bayer 1470) on the sympathetic system.

Authors:  H Schmitt; G Fournadjiev; H Schmitt
Journal:  Eur J Pharmacol       Date:  1970-05       Impact factor: 4.432

4.  Xylazine-induced depression and its antagonism by alpha adrenergic blocking agents.

Authors:  W H Hsu
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

5.  Halothane-sparing effect of xylazine in dogs and subsequent reversal with tolazoline.

Authors:  W J Tranquilli; J C Thurmon; J E Corbin; G J Benson; L E Davis
Journal:  J Vet Pharmacol Ther       Date:  1984-03       Impact factor: 1.786

6.  The alpha adrenoceptor antagonist properties of idazoxan in normal subjects.

Authors:  H L Elliott; C R Jones; J Vincent; C B Lawrie; J L Reid
Journal:  Clin Pharmacol Ther       Date:  1984-08       Impact factor: 6.875

7.  Neurochemical lesion of the locus coeruleus of the rat does not suppress the sedative effect of clonidine.

Authors:  S Nassif; E Kempf; B Cardo; L Velley
Journal:  Eur J Pharmacol       Date:  1983-07-15       Impact factor: 4.432

8.  Antagonism of xylazine sedation by 4-aminopyridine and yohimbine in cattle.

Authors:  J V Kitzman; N H Booth; R C Hatch; B Wallner
Journal:  Am J Vet Res       Date:  1982-12       Impact factor: 1.156

9.  Studies on RX 781094: a selective, potent and specific antagonist of alpha 2-adrenoceptors.

Authors:  J C Doxey; A G Roach; C F Smith
Journal:  Br J Pharmacol       Date:  1983-03       Impact factor: 8.739

10.  Hemodynamic effects of xylazine in the calf.

Authors:  K B Campbell; P A Klavano; P Richardson; J E Alexander
Journal:  Am J Vet Res       Date:  1979-12       Impact factor: 1.156

View more
  1 in total

1.  Alpha2-adrenergic impact on hypothalamic magnocellular oxytocinergic neurons in long evans and brattleboro rats: effects of agonist and antagonists.

Authors:  Jana Bundzikova; Zdeno Pirnik; Dora Zelena; Jens D Mikkelsen; Alexander Kiss
Journal:  Cell Mol Neurobiol       Date:  2009-03-17       Impact factor: 5.046

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.